Shattuck Labs initiated with a Buy at UBS

Needham raised its price target for Shattuck Labs (STTK) to $19 from $17, citing plans for a Phase 2 trial of SL-325 in hidradenitis suppurativa. The stock has surged 87% year-to-date, with analysts maintaining a strong buy consensus. The company expects trial data in 2028, and the hidradenitis suppurativa market is projected to reach $5 billion by 2030. Multiple analysts have recently evaluated STTK, with varying price targets and ratings.

Shattuck Labs (STTK) plans a Phase 2 trial for SL-325 in hidradenitis suppurativa, enrolling 150 patients. The trial will evaluate two doses against placebo, with primary endpoints at Week 16. Data is expected in 2028. The company also appointed Shoba Ravichandran as SVP, Clinical Development, and confirmed its cash runway extends into 2029.

Shattuck Labs (STTK) plans to start a Phase 2 trial in 2026 for SL-325 in hidradenitis suppurativa, with data expected in 2028. The company also appointed Shoba Ravichandran as Senior Vice President, Clinical Development. Cash runway is expected to last until 2029.

Strattec Security Corporation reported record annual revenue of $579.4 million for 2026, driven by pricing, cost actions, and operational improvements. The company reorganized its product portfolio and realized $6 million in restructuring savings, expanding gross margin to 16.5%. Strattec anticipates a challenging 2027 with a 2% decline in North American production and targets long-term gross margins of 18% to 20%. The company maintains a debt-free balance sheet with $108.2 million in cash and p

Shattuck Labs (STTK) rose 4.91% after two analysts initiated coverage with positive ratings. TD Cowen rated it buy, while Raymond James gave a strong buy and $18 price target. Both highlighted SL-325, a drug candidate for inflammatory bowel disease, citing its novel mechanism. The company reported $208.3M in cash and expects funding into 2029. Phase 2b trial for SL-325 is set to start in Q3.

H.C. Wainwright cut its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18 while keeping a Buy rating, after Shattuck reported Q2 2026 results on Aug. 11. Shattuck expanded its RECEPTIVE-CD1 Phase 2b trial to three doses and ~232 patients. The SL-325 Crohn’s trial remains on track for a Q3 2026 start. The article also notes a $75M public offering and warrant exercises.